Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
종목 코드 QNRX
회사 이름Quoin Pharmaceuticals Ltd
상장일Nov 01, 1989
CEODr. Michael Myers, Ph.D.
직원 수3
유형Depository Receipt
회계 연도 종료Nov 01
주소23 Hata'as Street
도시KFAR SABA
증권 거래소NASDAQ Capital Market Consolidated
국가Israel
우편 번호44425
전화97299741444
웹사이트https://quoinpharma.com/
종목 코드 QNRX
상장일Nov 01, 1989
CEODr. Michael Myers, Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음